A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer. - HER2+ MBC, RAD001 + trastuzumab+ paclitaxel.

ovartis0 sites5 target enrollmentStarted: TBDLast updated: May 6, 2024

Conditions

Trial Snapshot

No summary available.

•* Patients with histologically confirmed diagnosis of metastatic breast cancer demonstrating HER2-overexpression.
•* Patients must have progressive disease on therapy or within 3 months of the last trastuzumab dose for advanced disease OR recurrence within 12 months of completing trastuzumab-based therapy as (neo) adjuvant therapy.
•* Patients may have received adjuvant chemotherapy and one or more prior chemotherapies for advanced disease.

•* Patients receiving endocrine therapy for breast cancer < 2 weeks prior to study treatment start (endocrine therapy must have either failed in patients with hormone receptor positive disease or patients must be considered unsuitable for endocrine therapy).
•* Patients who received chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to study treatment start or patients who have received lapatinib < 2 weeks prior to study treatment start.
•* Patients who have previously received mTOR inhibitors.

Sponsor